The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | An update from ASH 2023: advancements in NHL treatment
Tycel Phillips, MD, City of Hope, Duarte, CA, provides an update on the latest advancements in non-Hodgkin lymphoma (NHL) treatment from ASH 2023. He discusses the Phase III SYMPATICO trial (NCT03112174), investigating the combination of ibrutinib plus venetoclax in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), as well as the progress that is being made into treatment with bispecific antibodies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, AstraZeneca, Bayer, Beigene, BMS, Cardinal Health, Epizyme, Incyte, Karyopharm, Pharmacyclics, Seattle Genetics
Research Funding: Abbvie, Bayer
